venetoclax and ibrutinib (I+VEN) + FCR
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intermediate Risk Chronic Lymphocytic Leukemia
Conditions
Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy
Trial Timeline
Sep 27, 2019 → Jan 30, 2025
NCT ID
NCT04010968About venetoclax and ibrutinib (I+VEN) + FCR
venetoclax and ibrutinib (I+VEN) + FCR is a phase 2 stage product being developed by AbbVie for Intermediate Risk Chronic Lymphocytic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04010968. Target conditions include Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04010968 | Phase 2 | Completed |
Competing Products
8 competing products in Intermediate Risk Chronic Lymphocytic Leukemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| Adalimumab | AbbVie | Approved | 85 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| Myfortic + Decortin | Novartis | Phase 3 | 77 |
| Etavopivat | Novo Nordisk | Phase 2 | 51 |
| ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo] | Barinthus Biotherapeutics | Phase 1/2 | 33 |